HC029-CPT / HC Biopharma - LARVOL DELTA

Development of conformation selective ITGB6 ADC (AACR 2026) - "The linker-payload was highly stable in both in vitro and in vivo studies, with minimal payload release (<0.0001%) from the ADC in plasma. Combining ITGB6 disease state selectivity, unique conformational epitope, effector null Fc, extra stable linker payload and safety profile, HC029-CPT expects to achieve a much broader therapeutic window compared to conventional ITGB6 ADC targeting therapeutics."

ADC • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • ITGB6